Shares of Humacyte, Inc. (HUMA) surged over 11% in trading on Thursday, October 18, fueled by a wave of positive analyst ratings and reports from several Wall Street firms. The biotech company's stock price soared amidst growing investor optimism and confidence in its prospects.
Leading the bullish sentiment was TD Cowen analyst Josh Jennings, who reiterated a "Buy" rating on HUMA and set a price target of $10.00. Jennings' favorable outlook highlighted the potential of Humacyte's regenerative medicine technology and its potential to drive future growth.
Piper Sandler analyst Allison Bratzel also weighed in, maintaining a "Hold" rating on the stock but raising the firm's price target to $6.00. While more cautious, Bratzel's revised target suggests potential upside for HUMA based on the company's ongoing development efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.